LB Pharmaceuticals presents new preclinical data for LB-102 at ECNP
LB Pharmaceuticals (LBRX) presented new preclinical data supporting LB-102’s bimodal mechanism of action and highlighted ongoing late-stage clinical development programs at the 39th ECNP Congress.